Entradas

RT @ASBMR: ASBMR is proud to announce new metrics for #JBMR, with a 2022 Impact Factor of 6.390 and a CiteScore of 11.3 (98th percentile), and @JBMRPlus which received its first CiteScore of 5.0 (83rd percentile)! Congratulations to all of our Editors, Reviewers, and Authors! https://t.co/jXZ3ZOzQOe

RT @ASBMR: ASBMR is proud to announce new metrics for #JBMR, with a 2022 Impact Factor of 6.390 and a CiteScore of 11.3 (98th percentile), and @JBMRPlus which received its first CiteScore of 5.0 (83rd percentile)! Congratulations to all of our Editors, Reviewers, and Authors! https://t.co/jXZ3ZOzQOe — Gaston Ramirez (@GastonR48222321) Jun 30, 2022 from Twitter https://twitter.com/GastonR48222321 June 30, 2022 at 05:26PM

RT @ASBMR: Authors from a new #JBMR study assessed the characteristics of individuals with biallelic and monoallelic SLC34A3 variants #ASBMR @Tobias_B_Huber @KlaRo2021 https://t.co/vu3y6N6pHD https://t.co/yJYkHn7IM0

RT @ASBMR: Authors from a new #JBMR study assessed the characteristics of individuals with biallelic and monoallelic SLC34A3 variants #ASBMR @Tobias_B_Huber @KlaRo2021 https://t.co/vu3y6N6pHD https://t.co/yJYkHn7IM0 — Gaston Ramirez (@GastonR48222321) Jun 30, 2022 from Twitter https://twitter.com/GastonR48222321 June 30, 2022 at 11:01AM

RT @ASBMR: The objective of a new #JBMR clinical trial was to evaluate the potential therapeutic advantage of Ca-Cit in comparison with calcium carbonate in HypoPT, on nephrolithiasis risk factors #ASBMR #openaccess #freetoread @WileyBiomedical https://t.co/zvEGs8Mggn https://t.co/tmSpGHaIvT

RT @ASBMR: The objective of a new #JBMR clinical trial was to evaluate the potential therapeutic advantage of Ca-Cit in comparison with calcium carbonate in HypoPT, on nephrolithiasis risk factors #ASBMR #openaccess #freetoread @WileyBiomedical https://t.co/zvEGs8Mggn https://t.co/tmSpGHaIvT — Gaston Ramirez (@GastonR48222321) Jun 30, 2022 from Twitter https://twitter.com/GastonR48222321 June 30, 2022 at 08:15AM

RT @ASBMR: The purpose of a new study published in #JBMR was to characterize FD lesion progression in children, and to identify clinical variables associated with progressive disease #ASBMR @VLSzymczuk @AlisonBoyceMD https://t.co/gSsoi87we4 https://t.co/754cg6RZXb

RT @ASBMR: The purpose of a new study published in #JBMR was to characterize FD lesion progression in children, and to identify clinical variables associated with progressive disease #ASBMR @VLSzymczuk @AlisonBoyceMD https://t.co/gSsoi87we4 https://t.co/754cg6RZXb — Gaston Ramirez (@GastonR48222321) Jun 29, 2022 from Twitter https://twitter.com/GastonR48222321 June 29, 2022 at 05:25PM

Les Compartimos una publicacion de IOF https://t.co/Q4fbZVG4hs https://t.co/2yd6L55RNK

Les Compartimos una publicacion de IOF https://t.co/Q4fbZVG4hs https://t.co/2yd6L55RNK — Gaston Ramirez (@GastonR48222321) Jun 29, 2022 from Twitter https://twitter.com/GastonR48222321 June 29, 2022 at 02:51PM

Les Compartimos una publicacion de ASBMR https://t.co/Q4fbZVG4hs https://t.co/Cy06kkTmCX

Les Compartimos una publicacion de ASBMR https://t.co/Q4fbZVG4hs https://t.co/Cy06kkTmCX — Gaston Ramirez (@GastonR48222321) Jun 29, 2022 from Twitter https://twitter.com/GastonR48222321 June 29, 2022 at 12:56PM

RT @ASBMR: A new longitudinal cohort study published in #JBMR examined the hazard of hip fractures in male former athletes and population controls and in relation to exercise volume and intensity in later years #ASBMR @JKaprio @WileyBiomedical https://t.co/1AP0OsTUvF https://t.co/rOZVVn3giK

RT @ASBMR: A new longitudinal cohort study published in #JBMR examined the hazard of hip fractures in male former athletes and population controls and in relation to exercise volume and intensity in later years #ASBMR @JKaprio @WileyBiomedical https://t.co/1AP0OsTUvF https://t.co/rOZVVn3giK — Gaston Ramirez (@GastonR48222321) Jun 29, 2022 from Twitter https://twitter.com/GastonR48222321 June 29, 2022 at 11:01AM